Jim Cramer: Why Investors Should Stick With Danaher After Earnings

Danaher's Recent Struggles and Resilience

• 💡 For years, Danaher was considered one of the best-run conglomerates, delivering over 1,000% returns in two decades.
• ⚠️ Since the pandemic, the stock has faced challenges including China's slow recovery, customer over-ordering, a weak IPO market, and government spending cuts.
• 📉 Despite these headwinds, Cramer notes that the company has a history of strong performance and he has previously bought the stock on weakness.

Q2 Earnings and Investor Reaction

• 📊 Danaher reported a strong second quarter with a revenue beat, steady organic growth, and better-than-expected margins, including a 16-cent earnings beat.
• 📉 Initially, the stock was heavily punished, dropping nearly 7% in pre-market trading, causing Cramer significant concern.
• 📈 However, the stock rebounded, finishing up 1% on Tuesday and rallying further in subsequent days, indicating a positive shift in investor sentiment.

Key Business Segments and Growth Drivers

• 🔬 The biotechnology segment, Danaher's highest-margin business, showed 8% sales growth and operating margin expansion.
• 🚀 The bioprocessing division, a $6 billion business, is showing signs of recovery with positive order trends and a book-to-bill ratio around one.
• 🌟 Success with monoclonal antibodies, which constitute over 75% of bioprocessing unit sales, is a key positive indicator.

Challenges and Future Outlook

• ⚠️ China remains a concern, with sales down mid-single digits due to volume-based procurement and reimbursement changes impacting the diagnostics business.
• ✅ Despite the China issue, Cramer believes the good news from other segments, particularly bioprocessing, outweighs the bad.
• 🚀 He suggests that Danaher is at a tipping point and may be poised to return to its former strong performance, justifying continued investment.

Cramer's Investment Recommendation

• 🤝 Cramer is sticking with Danaher for the Charitable Trust and gives his blessing for others to buy the stock.
• 🎯 He advises waiting on managed healthcare stocks like Sigma until UnitedHealth reports to gain clarity on the sector's issues.
• 💡 Cramer believes that investors were too quick to judge Danaher's earnings, and a closer look reveals a fundamentally improving business.